EMA Collaborates with Physicians
The agency holds a workshop to strengthen collaboration with healthcare providers.
On April 19, 2016, the European Medicines Agency (EMA) held a workshop with representatives of general practitioners and family doctors to explore ways the agency can collaborate with physicians in order to involve them with EMA activities. The goals of the physician/EMA collaboration are for EMA to gain better understanding of the real-life use and impact of medicines and for doctors to understand how they can inform regulatory discussions.
The workshop let to the creation of an expert group composed of the physician representatives, which included 20 participants from three major organizations: the European Forum for Primary Care, the European Union of General Practitioners/Family Physicians, and the World Organization of National Colleges, Academies, and Academic Associates of General Practitioners/Family Physicians Europe. The expert group will be involved in a wide range of EMA activities including providing scientific advice to drug developers, input on feasibility and impact on patients of risk minimization measures, and review of product information and dissemination of information.
“General practitioners and family physicians play a key role in patient care; they often have the first contact with the patient and accompany them throughout the life of their condition,” explained EMA’s Executive Director Guido Rasi in a press release. “This is why we want to engage them more in our activities as their knowledge and experience on how a medicine is used and addresses patient needs in real life can greatly inform our decision making.”
Source: EMA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
